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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYAndrogens are widely used for treating Fanconi anemia (FA) and other human bonemarrow failure syndromes, but their mode of action
remains incompletely understood. Aged Fancd2/ mice were used to assess the therapeutic efficacy of oxymetholone (OXM) and its
mechanism of action. Eighteen-month-old Fancd2/ mice recapitulated key human FA phenotypes, including reduced bone marrow
cellularity, red cell macrocytosis, and peripheral pancytopenia. As in humans, chronic OXM treatment significantly improved these
hematological parameters and stimulated the proliferation of hematopoietic stem and progenitor cells. RNA-Seq analysis implicated
downregulation of osteopontin as an important potential mechanism for the drug’s action. Consistent with the increased stem cell
proliferation, competitive repopulation assays demonstrated that chronic OXM therapy eventually resulted in stem cell exhaustion.
These results expand our knowledge of the regulation of hematopoietic stem cell proliferation and have direct clinical implications
for the treatment of bone marrow failure.INTRODUCTION
Fanconi anemia (FA) is an autosomal recessive disorder
associated with birth defects, progressive bone marrow
failure, hematopoietic stem cell (HSC) depletion, and can-
cer predisposition. FA is caused by a disrupted FA-BRCA
network and is genetically heterogeneous, with at least 16
complementation groups and respective genes identified
so far (Kim and D’Andrea, 2012).
Progressive bone marrow failure is the primary cause of
morbidity and mortality in FA patients (Kutler et al.,
2003). Most patients develop marrow dysfunction
within the first decade of life. The symptoms range
from mild cytopenia in any lineage to severe aplastic
anemia, often initially with thrombocytopenia (Shima-
mura and Alter, 2010). Red cell macrocytosis is quite
common in FA patients and usually precedes the onset
of thrombocytopenia.
HSC transplantation is the only curative treatment for
bone marrow failure in FA. However, androgens have also
been widely used to treat cytopenia in FA, especially for pa-
tients unable to proceed to transplant or patients with high
transplant risk. The most commonly used androgen is
oxymetholone (OXM), which is an anabolic-androgenic
steroid and a synthetic derivative of testosterone (Shima-
mura and Alter, 2010). Androgen therapy raises blood
counts in 50% to 70% of individuals with FA and also
works for other forms of aplastic anemia (Dokal, 2003).90 Stem Cell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The AuthoDespite a long history of androgen use in bone marrow
failure syndromes, the mechanism whereby these mole-
cules boost blood counts remains enigmatic (Chute et al.,
2010). It has been suggested that androgens stimulate eryth-
ropoiesis through an increase in the production of erythro-
poietin (EPO). However, more recent studies have found no
close correlation between androgens and EPO levels (Chute
et al., 2010), leading others to speculate that androgens
might have a direct effect on bone marrow (T’Sjoen et al.,
2005). One recent in vitro study suggested that androgens
act by increasing telomerase activity and extending the life-
span of CD34+ stem/progenitor cells (Calado et al., 2009).
Multiple murine models of FA are available. Among
them, Fancd2/mice, Fancp/mice, and Fancc-Fancg dou-
ble knockoutmice represent human FApatient phenotypes
more closely than the others (Crossan et al., 2011;
Houghtaling et al., 2003; Parmar et al., 2010; Pulliam-Leath
et al., 2010; Zhang et al., 2010). Fancd2/mice recapitulate
the characteristic tumor susceptibility of FA and show an
2-fold decrease in hematopoietic stem and progenitor
cell (HSPC) populations and a very poor long-term repopu-
lating capacity of bone marrow (Parmar et al., 2010; Zhang
et al., 2010). Despite this, themice have no obvious anemia
in their peripheral blood at age 6 months, except for lower
platelet counts. Here, however, we found that 18-month-
old Fancd2/ mice developed spontaneous pancytopenia.
We then set out to investigate how OXM benefits FA pa-
tients using this aged Fancd2/ mouse model.rs
Figure 1. Eighteen-Month-Old Fancd2/
Mice Have Pancytopenia
(A) Complete blood counts in 18-month-old
Fancd2/ mutants (n = 15) and WT con-
trols (n = 25). WBC, white blood cells; RBC,
red blood cells.
(B) Reduced bone marrow cellularity in
Fancd2/ mice. Total nucleated bone
marrow cells were counted for each femur
bone. The data showed the relative change
(as percentage) of marrow cellularity in
mutant mice as compared with their litter-
mate WT controls and represented pooled
results from four pairs of mice.
(C) Fancd2/ mice have spleen abnormal-
ities. (Upper and middle panels) Small
spleens in two mutant mice. (Lower panel)
Larger spleen in a mutant mouse.
(D) Representative blood smear pictures of
Fancd2/ mice and gender-matched WT
littermate controls. The blue arrow in-
dicates a Howell-Jolly body; green arrow,
polychromatic cells; orange arrow, acan-
thocyte; yellow arrow, lymphocyte. Original
magnification 31,000.
(E) H&E staining of the bone sections.
(Left) Longitudinal section of the trabec-
ular bones (original magnification, 3100).
(Middle and right) Longitudinal section of
the cortical bones (original magnifications:
middle panels, 3 50; right panels, 3 400).
See also Table S1.
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Eighteen-Month-Old Fancd2/ Mice Have
Pancytopenia and Respond to OXM Treatment
We previously reported that 4- to 6-month-old Fancd2/
mice have reduced numbers of HSCs with no evidence
for anemia in peripheral blood except for low platelet
counts (Zhang et al., 2010, 2013). A follow-up investigation
on a larger cohort of mice at the same age confirmed
normal white and red blood cell counts and low platelet
counts and also revealed a slight but significant elevation
of mean corpuscular volume (MCV), which is a character-
istic clinical phenotype of human FA patients (Table S1
available online) (Shimamura and Alter, 2010). To trackStemthe progression of these defects, we followed a cohort of
Fancd2/ and WT mice until 18 months of age. Similar
to the findings in our earlier report (Houghtaling et al.,
2003), 5 of 17 mutant mice developed tumors (with 3 of
them being ovarian tumors) during this time period,
whereas only 1 of 20 WT mice had a tumor. Animals with
tumors were excluded from further analysis. We found
that cancer-free 18-month-old Fancd2/ mice had devel-
oped spontaneous pancytopenia with red blood cells,
white blood cells, hemoglobin levels, and platelet counts
all below the normal ranges seen in age-matched WT
controls (Figure 1A). Fancd2/ mice also showed a highly
elevated MCV compared withWTcontrols and a reduction
in bone marrow cellularity ranging from 25% to 75%Cell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Authors 91
Figure 2. OXM Treatment Improves Hematopoiesis
(A) OXM-treated Fancd2/ mice (n = 5) exhibited better
hematologic parameters than placebo-treated Fancd2/ controls
(n = 13).
(B) OXM-treated Fancd+/+ mice (n = 11) had better hematologic
parameters than placebo-treated Fancd2+/+ controls (n = 23). OXM
treatment started at weaning and continued for 17 months before
final harvest.
See also Figure S1.
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showed spleen defects, with 6 of 10 mice displaying small
spleens and 2 of 10 mice having splenomegaly (Figure 1C).
We consistently observed Howell-Jolly bodies, which are
often associated with decreased splenic function, in pe-
ripheral blood smears (Figure 1D). Large, oval-shaped mac-
rocytes and polychromatic cells (bluish red blood cells in
hematoxylin and eosin [H&E] staining) were also visible
in the peripheral blood of 18-month-old Fancd2/ mice92 Stem Cell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Autho(Figure 1D). In contrast, they were rare in age-matched
WT mice. Four of 10 of the old Fancd2/ mice had thick-
ening of the cortical bone and narrowing of the marrow
cavity typical of osteopetrosis (Figure 1E).
We next wished to test whether OXM could improve
these FA-associated hematologic abnormalities. The OXM
dose was chosen to be equivalent to 80% of the maxi-
mum dose for human patients (Shimamura and Alter,
2010). To assure that the compound had the expected bio-
logical activity, Fancd2/ and WT mice were treated with
either OXM-supplemented or placebo chow for 4 months.
At harvest OXM-treated animals had larger kidneys (Fig-
ures S1A and S1B), indicating that the androgenic dose
was sufficient and biologically active (Shukla et al., 1992).
Androgen is known to downregulate renal ornithine ami-
notransferase gene Oat (Levillain et al., 2005). As expected,
Oat mRNA expression level in OXM-treated mice was
reduced by 75% (Figure S1C), further confirming the bioac-
tivity of the OXM diet.
We then treated cohorts of 1-month-old Fancd2/ mice
and WT littermate controls with either OXM-supple-
mented chow or placebo diet and monitored them until
age 18 months. Importantly, mice on OXM exhibited
clearly improved hematological parameters, including
platelet counts, red blood cell counts, hematocrit, and he-
moglobin levels (Figures 2A and 2B), albeit with no signif-
icant changes in white blood cell counts. The long-term
OXM treatment also partially corrected the macrocytosis
typical for FA. Collectively, these results indicate that 18-
month-old Fancd2/mice recapitulated FA patient pheno-
types and that OXM benefited Fancd2/ mice at the level
of peripheral blood in the same way it does for human
patients.
Long-Term OXM Treatment Leads to Stem Cell
Exhaustion in Both Fancd2/ and WT Mice
We then sought to determine the effect of long-term OXM
administration on bone marrow HSPCs, immunopheno-
typically defined as c-KIT+SCA-1+LIN (KSL) cells. Cohorts
of 1-month-old Fancd2/ and WT mice were treated with
eitherOXM-supplemented chowor placebo diet andmoni-
tored until age 18 months. CD34KSL cells, a population
enriched with long-term HSCs, were then quantitated by
flow cytometry (Figure 3A). First, we compared the fre-
quencies of CD34KSL cells in these old mice with those
in young mice. As shown in Figure 3B, 18-month-old
Fancd2/ mice had significantly fewer CD34KSL cells
than 4-month-old Fancd2/mice, indicating a progressive
attrition of the HSC pool during the aging process.We then
examined the effect of OXM on the frequencies of
CD34KSL cells. Surprisingly, the CD34KSL proportions
of the nucleated bone marrow cells in OXM-treated
Fancd2/ andWTmice (0.005% and 0.019%, respectively)rs
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Fancd2/ mice) than those in placebo-treated Fancd2/
andWTmice (0.009% and 0.027%, respectively), as shown
in Figure 3B. These results indicate that long-term OXM
administration might cause stem cell exhaustion.
We next evaluated the function of the HSCs from
these older mice with the competitive repopulation assay
depicted in Figure 3C. Bone marrow cells of OXM-treated
mice were transplanted along with a fixed ratio of
ROSA26Tg/O genetically marked bone marrow cells (as com-
petitors) into lethally irradiated Fancc/ mice. Six months
after transplantation, peripheral blood chimerism was
measured using quantitative PCR for the three genotypes.
At transplantation, the donor mix contained Fancd2/
bone marrow cells and ROSA26Tg/O bone marrow cells at a
3:1 (Fancd2/ versus ROSA26Tg/O) ratio. Six months after
transplantation, this ratio for placebo-treated Fancd2/
bone marrow dropped to 1:150 (Figure 3D). This decrease
in repopulating ability is significantly worse than that of
3-month-old Fancd2/ mice under similar experimental
settings previously reported by us (Zhang et al., 2010,
2013) and suggests a progressive deterioration of long-
term HSC function in Fancd2/ mice as they age. In
contrast, placebo-treated WT bone marrow cells only suf-
fered marginal loss in their HSC repopulating capacity
with aging (Figure 3D). Interestingly and importantly, the
long-term HSC repopulating capacities of both Fancd2/
and WT bone marrow were reduced by 40% (p < 0.05)
in OXM-treatment groups (Figure 3D). Taken together,
these data indicate that OXM administration leads to loss
of long-term HSC function.
OXM Selectively Stimulates HSPC Proliferation in
Both Fancd2/ and WT Mice
Increased cell cycle entry has been associatedwith eventual
stem cell exhaustion in several models (Orford and Scad-
den, 2008). To understand what drove the loss of long-
term HSC function after chronic OXM administration,
the cell cycle status of HSPCs in OXM-treated mice was
determined. Fancd2/mice and controls were given either
OXM diet or placebo for 4 months starting at 1 month of
age. We previously reported that Fancd2/ KSL cells lose
quiescence and display enhanced cell cycle entry (Zhang
et al., 2010, 2013). Four months of OXM therapy were
insufficient to change the size of HSPC pool or affect
HSPC function in the colony-forming unit-spleen assay
(data not shown). Nonetheless, cell cycle analysis at this
time revealed that OXM administration profoundly stimu-
lated the proliferation of HSPCs. The cell cycle status was
measured with a well-established method combining
Hoechst 33342 staining (for DNA content) with intracel-
lular KI67 expression (expressed only in cycling cells, not
in quiescent G0 cells). As shown in Figure 4A, bothStemFancd2/ and Fancd2+/+ mice on OXM treatment had sub-
stantially fewer quiescent G0 KSL cells and a higher per-
centage of actively cycling ones (S-G2-M phases of the
cell cycle) than their placebo-treated littermate controls.
Upon OXM administration, the average G0 percentage of
KSL cells in Fancd2/ and Fancd2+/+ mice dropped from
24.1% and 48.4% to 14.0% and 35.1%, respectively (p <
0.0001 for both) (Figure 4B). Correspondingly, the average
S-G2-M proportions of KSL cells increased from 16.2% to
22.9% in mutant animals (p < 0.002) and from 9.4% to
13.0% inWTmice (p < 0.05) (Figure 4B). These results indi-
cate that OXM further enhanced the already accelerated
proliferation of FA HSPCs and drove them into active
cycling.
We then determined whether the proliferation-
enhancing effect of OXM was specific only to HSPCs. The
cell cycle profiles of more mature lineage-positive (LIN+)
cells from the same mice were evaluated. We found that
Fancd2/ LIN+ cells had a normal cell cycle status (Fig-
ure 4C). Interestingly, the G0 and S-G2-M proportions of
LIN+ cells were unchanged after OXM administration in
both mutant and WT (Figures 4C and S2). In addition, we
also examined the cell cycle status of LINc-KIT+SCA-1
cells, a population that includes common myeloid pro-
genitors, granulocyte/monocyte progenitors, megakaryo-
cyte/erythroid progenitors, and other cells. Although
Fancd2/ LINc-KIT+SCA-1 cells showed slightly reduced
quiescence compared with their WT counterparts, neither
Fancd2/ nor WT LINc-KIT+SCA-1 cells showed in-
creased proliferation in response to OXM administration
(Figure S3). These results indicated that OXM did not
broadly stimulate blood cell proliferation, but acted selec-
tively at the level of HSPCs.
RNA-Seq Analysis Discovers Transcriptional Changes
in Fancd2/ HSPCs
We next wished to compare the transcriptomes of Fanconi
mutant and normal HSPCs. KSL cells were sorted by flow
cytometry after 3 months of OXM administration and
used for RNA-Seq gene expression analysis (Wang et al.,
2009). Three individual samples (pooled from five mice
for each sample) were processed for each experimental con-
dition, with combined reads (aligned to unique RefSeq
genes) per condition in the range of 100 to 200 million.
As shown in Table S2, Fancd2/ KSL cells showed clear
changes in mRNA expression profiles compared with WT
controls: 430 genes were downregulated by more than
1.5-fold, whereas 159 genes were upregulated. As expected
fromprevious work (Houghtaling et al., 2003), we observed
a 2.5-fold reduction of Fancd2 mRNA expression level in
Fancd2/ KSL cells, confirming the reliability of the RNA-
Seq analysis. Whole bone marrow cells were also analyzed
in parallel; genes enriched in KSL cells as compared withCell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Authors 93
Figure 3. Long-Term OXM Treatment Leads to Stem Cell Exhaustion in Both Fancd2/ and WT Mice
(A) Long-term (18 months) OXM administration in Fancd2/ mice reduced the size of bone marrow CD34KSL cell population.
Percentages on flow cytometry profiles were the mean of five to nine mice.
(B) Statistical quantification of CD34KSL cell proportion in whole nucleated bone marrow cells. (Left) Comparison of CD34KSL cell
frequency between 4- to 6-month-old and 18-month-old mice. (Right) Comparison of CD34KSL cell frequency between 18-month-old
mice on OXM treatment and those on placebo treatment. All the data are pooled results from multiple mice (n = 5–9 for each group).
(C) Strategy used in the competitive repopulation experiment. IR, BM, and mo denote irradiation, bone marrow and months, respectively.
(legend continued on next page)
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Figure 4. OXM Selectively Stimulates
Proliferation of KSL Cells in Both
Fancd2/ and Fancd2+/+ Mice
(A) Representative cell cycle profiles of KSL
cells from OXM-treated mice and their
gender-matched placebo-treated littermate
controls. Hoechst 33342 (for DNA content)
and FITC-conjugated antimouse KI67 (for
G0/G1 discrimination) were used in com-
bination to distinguish cells in G0, G1, and
S-G2-M phases of the cell cycle. The de-
noted percentage for each gate was from a
typical experiment. The mean percentage of
multiple mice for each group was shown in
the main text.
(B) Statistical quantification of the cell
cycle analysis on KSL cells in OXM- versus
placebo-treated mice. Data represent the
mean values from multiple mice (n = 9 for
both OXM and placebo groups of Fancd2/
mice, n = 13 for Fancd2+/+ placebo group,
and n = 11 for Fancd2+/+ OXM group).
(C) Statistical quantification of the cell
cycle analysis on LIN+ cells in OXM- versus
placebo-treated mice. Data represent the
mean values from multiple mice (n = 9 for
either OXM or placebo group of Fancd2/
mice, n = 11 for Fancd2+/+ placebo group,
and n = 10 for Fancd2+/+ OXM group).
See also Figures S2 and S3.
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scriptional downregulation (by 1.8-fold) of Cdkn1c in
Fancd2/ KSL cells is particularly interesting since its pro-(D) In vivo competitive repopulation of OXM-treated (or control) test
Three donors were evaluated for each experimental group; % chimeris
derived cells. Results from multiple recipients (seven to nine mice per
presented as mean ± SEM.
See also Table S8.
Stemtein product p57 is critically required for maintaining
quiescence in long-term HSCs (Tesio and Trumpp, 2011).
Consistent with its important function in HSCs, our datadonor bone marrow and ROSA26Tg/O competitor bone marrow cells.
m refers to the percentage of test donor-derived cells in all donor-
group) were pooled together for each experimental group. Data are
Cell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Authors 95
Table 1. Pathways Significantly Changed in Fancd2/ HSPCs as
Compared with WT HSPCs
Pathway Change FDR Scorea
Cell differentiation down 0.001
Cell cycle and its regulation up 0.002
Mitogenic signaling down 0.016
Nuclear receptor signaling down 0.022
Inflammatory and immune response up 0.060
aFDR denotes false discovery rate. The FDR cutoff for pathway analyses was
set at 0.10. Detailed gene lists for some important pathways were shown in
Table S4. See also Tables S2 and S3.
Table 2. Genes Differentially Changed in Both Fancd2/ and
WT HSPCs in Response to OXM Administration
Gene Symbol Gene ID Fold Change Q Valuea
Centromere
protein F
Cenpf NM_001081363 1.5 0.000
Marker of
proliferation Ki-67
Mki67 NM_001081117 1.4 0.000
Secreted
phosphoprotein 1
Spp1 NM_009263 10.5 0.025
20-50 oligoadenylate
synthetase-like 2
Oasl2 NM_011854 1.5 0.03
aQ value cutoff was set at 0.05. See also Figure S6 and Tables S5 and S7.
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KSL cells as compared with whole bonemarrow cells (Table
S3). In addition, the critical DNA-damage response gene
Rad51 was also upregulated in Fancd2/ KSL cells as ex-
pected since FA cells often show persistent DNA damage
foci due to insufficient DNA interstrand crosslink repair.
Gene ontology analysis revealed key pathways to be
significantly altered in Fancd2/ KSL cells (summarized
in Table 1). Consistent with the abnormal cell cycle status
discovered by flow cytometry analysis, the pathways of
cell cycle activation and its regulation were enhanced in
Fancd2/ KSL cells. Specifically, many cell cycle genes
showed transcriptional changes in Fancd2/ KSL cells,
including the upregulation of Cdk1, Ccna2, Ccnb1, Ccnb2,
Ccnd1, Cdc25C, Cdkn3, Cdca3, Cdca8, Cks1b, Nek2, Birc5,
Cdca5, Mad2l1, Pttg1, and Aurka (Table S4). Some of these
genes are known cell cycle regulators in HSCs (Rossi et al.,
2012; Tesio and Trumpp, 2011). Surprisingly, we also
noticed that a group of genes involved in immune re-
sponses and inflammation, comprising Cfp (Properdin),
Socs2, Ccr1, Ccr2, Ccr5, Chga (Chromogranin A), Ifi30
(Interferon Gamma-Inducible Protein 30), Lgmn, Txn, and
Sell (selectin L), were upregulated in Fancd2/ KSL cells
(Tables 1 and S4).
Changes in mRNA Expression Profile in HSPCs in
Response toOXMAdministration Reveal aMechanism
behind OXM’s Proliferation-Stimulating Effect
In order to interrogate the mechanism underlying the cell
cycle changes induced by OXM, we performed RNA-Seq
on HSPCs from the placebo and OXM treatment groups.
Considering that the proliferation-enhancing effect of
OXM was observed in both Fancd2 mutant and WT mice,
we focused our analysis on OXM-altered genes shared by
both genotypes. Only four genes (Table 2) changed their
expression levels significantly after OXM administration
in both Fancd2/ and WT mice. Both mKi67 and Cenpf
are cell cycle-regulated genes and proliferation markers.96 Stem Cell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The AuthoIn fact, the mKi67-encoded protein is the antigen recog-
nized by anti-KI67 antibody, the same antibody used in
our cell cycle analysis. The RNA-Seq data demonstrated
that both genes were expressed at lower levels in KSL cells,
as compared with whole bone marrow cells, and were
mildly but significantly upregulated after OXMadministra-
tion, further confirming our observation above that OXM
stimulates the proliferation of HSPCs in both Fancd2/
and WT mice.
Two genes, Spp1 andOasl2, were significantly downregu-
lated after OXM administration. Spp1 in particular was
affected and was suppressed over 10-fold (Table 2). Spp1
was expressed at similar levels in both HSPCs and whole
bone marrow cells (Table S3) and encodes secreted phos-
phoprotein 1 (also known as osteopontin), a cytokine
known to upregulate the expression of certain interferons
and interleukins. The other gene Oasl2 was enriched 11-
fold in HSPCs compared with whole bone marrow cells
(Table S3). Oasl2 encodes 20-50 oligoadenylate synthetase-
like 2 and belongs to a highly conserved family of inter-
feron-induced enzymes (Hovanessian and Justesen,
2007). Since both genes are known to inhibit proliferation
(Kumar and Mendelsohn, 1989; Nilsson et al., 2005), it is
plausible that OXM-mediated suppression of these genes
underlies its proliferation-promoting effects.
It is worth noting that no expression changes in mTert
RNA expression levels were detected in response to OXM
administration (Table S5), although mTert mRNA was en-
riched 13-fold in HSPCs of both Fancd2/ and WT mice
(Table S3). Therefore, the induction of telomerase (Calado
et al., 2009) is unlikely to underlie the activity of OXM dur-
ing chronic administration.
OXM Suppresses Spp1 Transcription in an Androgen
Receptor-Dependent Manner
Although it has never been reported that Spp1 is an and-
rogen-target gene, a genome-wide profiling of androgen re-
ceptor (AR) binding identified one AR target site in intron 3rs
Figure 5. OXM Suppresses Spp1
Transcription through the Mediation
of AR
(A) OXM suppressed Spp1 gene expression in
cultured 7F2 mouse osteoblasts. RNA input
was normalized based on glyceraldehyde
3-phosphate dehydrogenase mRNA expres-
sion. The Spp1 expression level in placebo-
treated 7F2 cells was set at 1 as a reference.
Data are pooled results from four indepen-
dent experiments. Data are presented as
mean ± SEM.
(B) OXM suppressed Spp1 gene expression
in kidneys. Data are pooled results from
multiple female mice (n = 4 for each
group).
(C) Spp1 gene expression levels were not
suppressed by OXM in the kidneys of AR-
deficient mice. Data are pooled results
from multiple female mice (n = 3 for each
group).
(D) OXM stimulated KSL cell proliferation
through the mediation of AR. Data are pooled results from multiple mice (n = 14 for placebo AR+/+ group, n = 13 for OXM AR+/+ group, and
n = 12 for either OXM or placebo group of AR/ mice). NS denotes not significant.
See also Figures S4 and S5 and Table S6.
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Bioinformatics analysis using UCSC PhyloP basewise
conservation tool (http://genome.ucsc.edu/) further re-
vealed that this AR target site was highly conserved across
different species (Figure S4B). Furthermore, a BLAT search
with the human AR target sequence returned an intronic
sequence with 84% DNA sequence identity in the mouse
Spp1 gene. The Spp1-encoded osteopontin is known to be
produced by osteoclasts and osteoblasts (Nilsson et al.,
2005; Stier et al., 2005), but is also expressed in some soft
tissues such as the kidney (Hsieh et al., 2006). Since osteo-
blasts are difficult to purify from bone marrow, we tested
Spp1 transcriptional changes by quantitative RT-PCR in
cultured 7F2 mouse osteoblasts in vitro. As shown in Fig-
ure 5A, 24 hr of treatment with OXM significantly reduced
Spp1 mRNA level in osteoblasts (p < 0.005). We also
measured Spp1 gene expression levels in vivo by quantita-
tive RT-PCR. As shown in Figure 5B, Spp1 mRNA levels in
the kidneys of chronic OXM-treated mice were 80% lower
than those in placebo-treated, gender-matched controls
(p < 0.0001). Immunohistochemistry staining of bone sec-
tions with an anti-Spp1 antibody confirmed the downregu-
lation of Spp1 in the bone samples fromOXM-treatedmice
(Figure S4C).
Moreover, the suppression of Spp1 transcription by OXM
was dependent on the AR. Spp1 mRNA levels were un-
changed by OXM treatment in AR-deficient mice of
C57BL/6J strain background (p = 0.77; Figure 5C). In
contrast, WT mice of the same strain showed clear OXM-Stemmediated suppression of Spp1 transcription (p < 0.0001;
Figure 5C).
To further understand the correlation between Spp1
mRNA levels and HSPC proliferation, we then treated AR-
deficient mice with OXM for 4 months and examined the
cell cycle profiles of their KSL cells. 44.5% (±2.6%) of KSL
cells in OXM-treated AR/ mice were in the G0 stage of
the cell cycle, similar to 43.8% (±2.5%) observed in pla-
cebo-treated AR/ mice (p = 0.84; Figure 5D). Similarly,
the proportions of KSL cells in S-G2-M phase in both
OXM-treated and placebo-treated AR/ mice were at the
same levels (p = 0.92; Figure 5D). In contrast, inWTcontrol
mice of the same C57BL/6J background, significant loss of
quiescence and enhanced cycling in OXM-treated group
(p < 0.05; Figure 5D) were seen. Taken together, these re-
sults suggest that OXM stimulates HSPC proliferation
through AR-mediated transcriptional suppression of Spp1.
Changes in mRNA Expression Profile in Basophilic
Erythroblasts in Response to OXM Rule Out an
EPO-Mediated Mechanism of Action by OXM
Finally, we sought to test the previously proposed hypoth-
esis that OXM might activate the EPO pathway in early
erythroid progenitors to enhance erythropoiesis (Chute
et al., 2010). A group of WT mice was injected with EPO
for 3 consecutive days. Complete blood count analysis re-
vealed that the mice on EPO treatment showed higher he-
moglobin, an effect similar to that of OXM (Figure S5A).
However, the EPO-treatedmice also had higherMCV levelsCell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Authors 97
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caused by the shift of large, immature reticulocytes into cir-
culation as a consequence of EPO-stimulated stress erythro-
poiesis (Finch, 1982). The macrocytosis effect from EPO
was in clear contrast to OXM’s ability to alleviate macrocy-
tosis under our experimental conditions, suggesting a
divergence between the two drugs’ mechanisms of action
in promoting erythropoiesis.
In addition, the serum levels of EPO in mice on OXM or
placebo were measured, and no difference was found (Fig-
ure S5B), further indicating that OXM did not function
through the activation of the EPO pathway.
In order to further understand this issue and identify any
potential targets of OXM in erythroid progenitors, we next
sorted TER119high/CD71high/FSChigh basophilic erythro-
blasts by flow cytometry and investigated the differential
mRNA expression profiles with and without OXM admin-
istration inWTmice. Basophilic erythroblasts were chosen
because this population expresses abundant Epo receptor
(Singbrant et al., 2011). OXM had no effect on the abun-
dance of this population (data not shown). No significant
differences at all in gene expression were found between
OXM-treated WT erythroid progenitors and their placebo-
treated counterparts, with no gene displaying an expres-
sion change higher than 1.2-fold. Importantly, no upregu-
lation of EPO-inducible genes such as Socs1, Socs2, Socs3,
and Cish (Ingley, 2012) was seen in WT mice treated with
OXM (Table S6). In addition, there was no differential
expression of the well-known EPO target transferrin recep-
tor or any other major players of the Epo-R signaling
network such as Bcl2l1, Cdc25a, Btg3, Ccnd2, Lyl1, Pim3,
and Tnfrsf13c (Singh et al., 2012) (Table S6). These results
further confirm that EPO does not play a role in the action
of OXM in the erythroid lineage.
It is also important to mention that Spp1 mRNA ex-
pression was undetectable in basophilic erythroblasts
(Table S7), whereas it was robustly expressed in HSPCs.DISCUSSION
Although OXM has been used for patients with aplastic
anemia including FA for many years, its mechanism of ac-
tion remains poorly understood. The studies described
herein provide significant information on how this widely
used drug affects hematopoiesis and exerts therapeutic
benefit. We found that OXM significantly reduced quies-
cence and promoted proliferation in KSL hematopoietic
stem/progenitor cells. This effect was not specific to FA
HSPCs, but affected WT mice just as strongly. The percent-
age of actively cycling cells increased by at least 50% in
both genotypes. Interestingly, the effect of OXM on the
cell cycle was specific only to HSPC in both mutant mice98 Stem Cell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Authoand controls. Other hematopoietic lineages in the bone
marrow did not divide more frequently in response to the
drug. This finding indicates that OXM administration has
a direct effect on the HSPC compartment and is consistent
with the fact that the drug is known to increase the
numbers of all blood lineages in humans, including red
blood cells, platelets, and neutrophils (Shimamura and
Alter, 2010). Although theHSPCs clearly cyclemore rapidly
on OXM, the number of immunophenotypically defined
stem cells did not increase in either mutants or WT mice.
This suggests that the newly generated cells rapidly feed
into the progenitor compartment rather than generating
new stem cells by self-renewal. In fact, our data show that
chronic OXM administration eventually results in stem
cell exhaustion. The long-term repopulating ability of
stem cells from OXM-treated mice was significantly lower
than those of placebo-treated controls. This was not unex-
pected, given the fact thatmultiple genetic mutations asso-
ciated with reduced stem cell quiescence have been shown
to result in eventual stem cell depletion (Orford and Scad-
den, 2008). We have previously shown that FA HSPCs
already have an accelerated cell cycle and interpreted this
finding as a homeostatic mechanism that compensates
for the increased loss of stem cells in this disease (Zhang
et al., 2010). The administration of OXM can further en-
hance this compensatory mechanism, at least temporarily,
and indeed does improve multiple hematological parame-
ters in FA mice. However, our data predict that OXM will
not provide a permanent rescue of hematopoiesis and
that a more definitive method of treatment will be eventu-
ally needed, even in good early responders. In fact, many
FA patients eventually become androgen resistant even if
their initial response was positive (Shimamura and Alter,
2010). It is possible that HSCs in these patients have been
completely depleted at later stage of the treatment.
The analysis of the transcriptome of OXM-treated HSPCs
was revealing. First, the data showed very clearly that the
mRNA levels of mTERT were not different between treated
and untreated animals. In vitro studies by others have
shown that OXM can enhance telomerase activity through
estrogen receptor-mediated signaling in short-term assays
(Calado et al., 2009). However, this effect was not observed
in the long-term in vivo studies described herein. Further-
more, enhanced expression of telomerase, even if present,
would not explain the observed effect on stem cell quies-
cence. We conclude that increased telomerase activity is
not the primary mechanism by which OXM acts in vivo.
Second, the RNA expression data confirmed that the
cell cycle was changed by OXM at the transcriptional
level. For example, the mRNA encoding the KI67 antigen
was clearly induced. More importantly, however, the
data demonstrated a profound (10-fold) decrease in
osteopontin mRNA. This effect of OXM on osteopontinrs
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rectly by an AR-target site in Spp1 gene. This finding has
clinical implications because it indicates that the use of
AR antagonists (Gao, 2010) is not a viable strategy to
ameliorate the masculinizing side effects of androgens in
bone marrow failure patients.
Although osteopontin is best known as a protein found
in bone (Nilsson et al., 2005; Stier et al., 2005), it is ex-
pressed at robust levels in the stem cells themselves, as evi-
denced by our RNA-Seq analysis of KSL cells and previously
published gene expression database on SPKSL cells (Cham-
bers et al., 2007) (Figure S6). Its precise function inHSPCs is
unclear, but it has been shown that Spp1/ stem cells have
an accelerated cell cycle (Nilsson et al., 2005). It has gener-
ally been thought that osteopontin expressed by bone cells
in the HSC niche acts on stem cells in a paracrine mode
(Nilsson et al., 2005; Stier et al., 2005). Our data indicate
that this protein may also have a cell autonomous effect
in stem cells. Future studies with cell-type specific knock-
outs will be required to address this hypothesis. A second
gene, Oasl2, was also suppressed by OXM. Oasl2 (20-50 oli-
goadenylate synthetase-like 2), has not been well studied
in HSPCs, despite its known high expression in hemato-
poietic tissues (Hartmann et al., 1998; Tiefenthaler et al.,
1999). Our RNA-Seq data further showed thatOasl2 expres-
sion was 11-fold higher in KSL cells than that in whole
bone marrow cells. Several publications have identified its
proapoptotic and antiproliferative roles in other cell types
(Ghosh et al., 2001; Kumar and Mendelsohn, 1989), but
its high expression level in KSL cells suggests that it might
have a direct role in HSPC function. As a cytokine, osteo-
pontin upregulates the expression of interferons and in-
terleukins. Conversely, Oasl2 is known to be induced by
interferons (Hovanessian and Justesen, 2007), promote
apoptosis, and suppress proliferation (Ghosh et al., 2001;
Kumar andMendelsohn, 1989). Collectively, it is tempting
to speculate that osteopontin and 20-50 oligoadenylate syn-
thetase-like 2 function in the same pathway to inhibit
HSPC proliferation. OXM’s primary mode of action would
be to transcriptionally repress this growth inhibitory
pathway.
Many publications have suggested that overexpression
of osteopontin may play a role in the biology of some
cancers, including acute myelogenous leukemia (Bando-
padhyay et al., 2014; Liersch et al., 2012), and that its
suppression could be therapeutically beneficial. Our data
suggest that OXM or other androgens could readily be
used for this purpose. OXM should be tested in preclinical
animal models of relevant tumors to determine whether it
impairs tumor growth.
Our results also shed light on another hypothesis re-
garding the mechanism of action of androgens in anemia.
Early work suggested that androgens stimulate erythropoi-Stemesis via the activation of EPO pathway. However, subse-
quent studies found no correlation between serum EPO
and androgen levels (Chute et al., 2010). Similarly, we
also observed no difference in serum EPO levels between
OXM- and placebo-treated mice, despite finding a substan-
tial increase in renalmass inOXM-treatedmice, a phenom-
enon well known to be associated with chronic androgen
administration (Shukla et al., 1992). Consistent with this,
RNA-Seq transcriptome analysis of early erythroid progen-
itors did not show any induction of critical EPO-inducible
genes or EPO target genes after OXM treatment. Moreover,
under our experimental conditions, OXM reduced the
MCV level whereas EPO causes macrocytosis, indicating a
clear divergence between the action of the two. Our data
therefore argue strongly against an EPO-mediated mecha-
nism of action for androgen therapy.
Our data also provide information on the pathophysi-
ology of FA itself. First, we found that the drastic accelera-
tion of cell cycling observed in Fancd2/ HSPCs is unique
to this blood cell population. No cell cycle abnormalities
were observed in mature hematopoietic lineages. Others
have found that the hypersensitivity of FA cells to acetalde-
hyde is also uniquely limited to HSPCs (Garaycoechea
et al., 2012) and that it is possible that the lack of stem
cell quiescence is mediated by aldehyde toxicity. Unfortu-
nately, OXM had no effect on the expression of any alde-
hyde-detoxifying genes in stem cells, including Aldh2. Sec-
ond, in the past, FAmousemodels have been considered to
be poor models of the human disease because they did not
develop readily detectable anemia. Our results, however,
indicate that Fancd2/ mice actually recapitulate the dis-
ease rather faithfully when the animals are observed for a
longer time period commensurate with the time it takes
to develop anemia in humans. We observed clear declines
in platelet counts, obvious red cell abnormalities, including
macrocytosis, and even osteopetrosis. We also found that
OXM therapy had similar effects to those reported in hu-
man FA patients, improving platelet counts, red blood
cell counts, and hemoglobin levels, with no changes in
white blood cell counts. Overall, we conclude that aged
Fancd2/ mutant mice are an adequate model for sponta-
neous bone marrow failure and can be used for preclinical
drug efficacy studies.
Finally and most importantly, we found critical gene
expression changes in HSPCs of Fancd2 mutant mice. The
changes in cell cycle-related genes and genes involved in
DNA damage responses were not surprising, given the
obvious lack of stem cell quiescence and the known role
of the FA pathway in DNA repair (Kim and D’Andrea,
2012). However, we also found significant changes in mul-
tiple genes involved in immune responses. Recentwork has
clearly shown that DNA damage can activate innate immu-
nity (Gasser et al., 2005) by signals emanating from theCell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Authors 99
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cytokine levels have long been known to be present in FA
(Nalepa and Clapp, 2014). We therefore hypothesize that
some genes upregulated in FA HSPCs may be part of an
innate immune response to DNA damage. In this model,
DNA damage-mediated signals originating from stem cells
eventually activate systemic inflammation and cytokine el-
evations. These proinflammatory cytokines can be toxic to
stem cells and cause further genomic damage, thus creating
a vicious circle resulting in bone marrow failure.EXPERIMENTAL PROCEDURES
Mice
Fancd2 mutant, Fancc mutant, and ROSA26 transgenic mice were
maintained on the 129S4 strain background as described before
(Zhang et al., 2010). AR/ mice were originally developed in Dr.
Kato’s lab and maintained on the C57BL/6J background (Shiina
et al., 2006). OXM was obtained from Sigma, milled into standard
rodent chow at 300 mg/kg diet (Bio-Serv), and given to the mice
upon weaning (3–4 weeks of age). For complete blood count and
KSL frequency analyses, the treatment continued for 17 months
until harvest. For cell cycle analysis and OXM biological activity,
the treatment continued for 4 months; for RNA extraction, the
treatment continued for 3 months. Recombinant human EPO
(Procrit from Amgen) was given in three consecutive doses at
3,000 IU on day 1, 1,000 IU on day 2, and day 3. All animals
were treated in accordance with the guidelines of the Institutional
Animal Care and Use Committee.
Cell Culture
7F2 mouse osteoblast (ATCC CRL-12557) cells were purchased
fromATCC. For in vitroOXM treatment, cells were split at the ratio
of 1:10 and plated with 5 mM OXM-supplemented medium.
Twenty-four hours later, cells were harvested for RNA isolation
with Trizol reagent.
Complete Blood Count
Complete blood counts were measured by IDEXX Laboratories to
monitor hematological parameters.
Histopathology
Bone marrow smears and peripheral blood smears were stained
with Wright-Giemsa Stain (Polysciences).
Flow Cytometry
Flow cytometry experiments were performed as described previ-
ously (Zhang et al., 2010). Propidium iodide was included as a
viability dye. Mouse IgG1 isotype control (for cell cycle analysis)
or fluorescence minus one controls (in all the other cases) were
used for gating. Cytometric data were analyzed using FlowJo soft-
ware v.9.6.1 (Tree Star).
Fractionation of erythroblasts at various stages of differentiation
in bone marrow was achieved by combining cell surface marker
staining of CD71 and TER119 with the analysis of cell size (based100 Stem Cell Reports j Vol. 4 j 90–102 j January 13, 2015 j ª2015 The Authon flow cytometric forward scatter intensity) (Singbrant et al.,
2011). Bone marrow cells were stained with FITC-conjugated anti-
mouse CD71 and PE-Cy7-conjugated antimouse TER119. The
TER119high/CD71high/FSChigh basophilic erythroblast fraction
was sorted on a Cytopeia Influx cell sorter equipped with four
lasers, allowing for excitation wavelengths of 355, 488, 561, and
633 nm.
Competitive Repopulation Assay
Whole bone marrow cells were isolated from OXM- or placebo-
treated mice. After red cell lysis, nucleated cells were counted
and mixed with competing ROSA26 bone marrow cells for trans-
plantation. Fancd2/ cells were mixed with ROSA26 cells at a 3:1
ratio, whereas Fancd2+/+ cells were mixed with ROSA26 at 1:1 ratio.
A total of 4 million mixed cells was used for retro-orbital injection
of each recipient Fancc/ mouse preconditioned with a split
whole-body lethal dose of 12 Gy irradiation (6 Gy each, 4 hr apart).
Six months after transplantation, DNAwas extracted for quantita-
tive real-time PCR analysis, and each original donor’s contribution
to peripheral blood was calculated to assess peripheral blood
chimerism. PCR primers were listed in Table S8.
RNA-Seq
RNA was extracted using Trizol reagent (Invitrogen), followed
by RNAeasy Mini Kit (QIAGEN) and DNase I treatment. RNA
quality was determined by an Agilent 2100 Bioanalyzer (Agilent
technology). Three samples per condition were processed to
ensure sufficient power for detecting any differentially ex-
pressed genes. For KSL libraries, each sample represented total
mRNA isolated from pooled KSL cells of five individual mice;
for basophilic erythroblast libraries, each library represented to-
tal mRNA isolated from basophilic erythroblasts of one individ-
ual mouse.
Libraries were constructed using TruSeq RNA Sample Preparation
Kit (Illumina) according to the manufacturer’s instructions and
sequenced as 51 base-length reads using Illumina HiSeq 2000
genome analyzer. All reads were mapped to the mouse reference
genome (version mm 9) using Bowtie short read aligner software
(http://bowtie-bio.sf.net). Data analysis was performed using
EdgeR GLM algorithms (McCarthy et al., 2012). Data mining and
pathway analysis were carried out with the MetaCore integrated
software suite (Thomson Reuters).
Serum EPO Test
Serum samples were tested for EPO levels using a mouse EPO-spe-
cific ELISA at Ani Lytics.
Statistical Analyses
Two-tailed, unpaired Student’s t tests were performed to calculate
p values using Prism 6.0c software (GraphPad Software). A p value
less than 0.05 was considered significant.
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Expression Omnibus), a public functional genomics data reposi-
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